Tirzepatide is an investigational and therapeutic peptide analog of the human GIP hormone. It is structured as a linear peptide containing 39 amino acids with a C20 fatty diacid portion attached to the lysine-16 residue. This structural modification enhances its stability and extends its elimination half-life to approximately 5 days by promoting albumin binding.

As a “twincretin” or dual GIP/GLP-1 receptor agonist, Tirzepatide activates both incretin hormone pathways. This dual mechanism stimulates insulin secretion and reduces glucagon secretion in a glucose-dependent manner. Furthermore, it is known to delay gastric emptying, reduce appetite, and improve insulin sensitivity. These combined actions make it a potent agent in studies related to glycemic control and metabolic regulation.

• CAS Number: 2023788-19-2

• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈

• Molecular Weight: 4813.5 g/mol